Tuberculosis, better known as TB, is characterised by a fever and persistent cough that can sometimes lead to coughing up blood. Not too long ago, many people believed it to be a problem we had under control. Unfortunately, in the last 30 years we have seen the return of this highly contagious and potentially deadly disease. There is now an estimated 28 million people at risk of death from TB by 2030.
GSK has been working for many years on a new candidate vaccine for tuberculosis. It has now been tested in a phase II clinical trial in TB-endemic regions of Africa. Excitingly, we have now licensed our TB candidate vaccine to the Bill & Melinda Gates Medical Research Institute for its continued development and potential use in the places who need it most; low-income countries with high prevalence of TB.
For the first time in almost a century, a major step has been taken towards finding a potential new vaccine for TB. Read more about the global fight against TB here.
For the classroom: The Fighting malaria classroom module will help build your students understanding of vaccines, global disease and innovation.
Header image: Macrophage engulfing a tuberculosis bacterium.